Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor

Author:

Sanders Don B.ORCID,Mayer-Hamblett Nicole,Rosenfeld MargaretORCID,Polinieni Deepika,Dasenbrook ElliottORCID,Szczesniak Rhonda,Cromwell Elizabeth A.ORCID

Funder

Cystic Fibrosis Foundation

Publisher

Elsevier BV

Reference21 articles.

1. Cystic fibrosis;Elborn;Lancet,2016

2. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Annals of the;Sawicki;Am Thorac Soc,2015

3. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis;Costa;Orphanet J Rare Dis,2022

4. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2022 Annual Data Report. Bethesda, MD: 2023.

5. Worldwide rates of diagnosis and effective treatment for cystic fibrosis;Guo;J Cyst Fibros,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3